BioCryst Pharmaceuticals BCRX Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One
Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One at other companies
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue.
The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioCryst Pharmaceuticals's debt securities, available-for-sale, fair value, maturity, allocated and single maturity date, year one.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioCryst Pharmaceuticals's debt securities, available-for-sale, fair value, maturity, allocated and single maturity date, year one?
- BioCryst Pharmaceuticals (BCRX) reported debt securities, available-for-sale, fair value, maturity, allocated and single maturity date, year one of $66.81M in Q1 2026.
- How has BioCryst Pharmaceuticals's debt securities, available-for-sale, fair value, maturity, allocated and single maturity date, year one changed year-over-year?
- BioCryst Pharmaceuticals's debt securities, available-for-sale, fair value, maturity, allocated and single maturity date, year one decreased by 64.8% year-over-year, from $189.9M to $66.81M.
- What is the long-term trend for BioCryst Pharmaceuticals's debt securities, available-for-sale, fair value, maturity, allocated and single maturity date, year one?
- Over 3 years (2022 to 2025), BioCryst Pharmaceuticals's debt securities, available-for-sale, fair value, maturity, allocated and single maturity date, year one has grown at a 15.7% compound annual growth rate (CAGR), from $119.54M to $185.01M.